Pro-Life Leader Expects Trump’s FDA Nominee to Tighten Mifepristone Rules

John Mize, head of Americans United for Life, told Fox News Digital that Dr. Heidi Overton, Trump’s choice to lead the Food and Drug Administration, would likely push for enhanced scrutiny of mifepristone. Overton currently works as Trump’s deputy assistant for domestic policy and holds well-documented pro-life positions. Mize said his organization is optimistic about her potential appointment as FDA commissioner.

Mize indicated he has held multiple discussions with Overton about the abortion medication. He believes she will examine mifepristone “objectively” and reveal what he characterizes as the drug’s harmful effects on women. The organization’s leader also expressed confidence that Overton understands the clinical risks associated with a medication carrying the FDA’s strongest warning label.

The timing of Overton’s nomination follows a high-profile case in North Carolina, where an 18-year-old woman faced accusations of using mifepristone and misoprostol to end a pregnancy at 31 weeks—far exceeding the drug’s federally approved 10-week window. Mize has directed Americans United for Life, which opposes abortion and euthanasia, for approximately two and a half years since the organization’s establishment in 1971.

Overton has publicly criticized abortion medications in previous policy work. In a 2023 brief for the America First Policy Institute, where she served as chief policy officer, she condemned federal efforts to expand access to these drugs. She specifically faulted the Biden administration for leveraging pandemic restrictions to justify allowing mifepristone and misoprostol to be mailed to patients.

Mifepristone blocks progesterone needed to maintain pregnancy, while misoprostol triggers contractions to expel fetal tissue. Together they account for roughly 65 percent of clinician-provided abortions as of 2023, according to the Guttmacher Institute—a substantial increase from 53 percent in 2020, before the Supreme Court reversed Roe v. Wade.

Mize cited a 2025 analysis by the Ethics and Public Policy Center showing an 11 percent serious adverse event rate among nearly 866,000 mifepristone cases studied between 2017 and 2023. The findings included complications like hemorrhaging, sepsis, and infection, though the medical community quickly disputed the study’s methodology and noted it lacked peer review or journal publication.

The FDA removed mifepristone’s in-person dispensing requirement in 2021 during the pandemic and later made the change permanent following safety review. Current regulations permit telehealth consultations followed by mail delivery through certified pharmacies. Mize wants stricter requirements reinstated, specifically an in-person physician visit before prescription issuance.

Mize characterized Overton as “measured” and “methodical,” warning that pro-life advocates should not anticipate rapid or sweeping regulatory changes. He suggested her first priorities would involve completing the FDA’s ongoing safety review, formally launched in September 2025 with no scheduled end date, followed by a comprehensive long-term evaluation of whether mifepristone should remain available.

Dr. Marty Makary stepped down as FDA commissioner in May after conflicts with Trump administration officials and Republican lawmakers who criticized his handling of the mifepristone review. If confirmed, Overton would assume responsibility for the unfinished examination. Mize stated his ultimate goal would be removing mifepristone from the market, though he acknowledged the nation may not be ready for such action.

Overton’s confirmation hearing has not been scheduled but is expected following the Senate’s return from summer recess on September 14.